Grafa News and Videos — Page 779

The U.S. Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

Agios Pharmaceuticals (NASDAQ:AGIO) announced that the European Commission has granted marketing authorization for Pyrukynd (mitapivat) to treat anemia in adult patients with alpha- or beta-thalassemia.

Imperial Petroleum (NASDAQ:IMPP) announced its financial and operational results for the first quarter of 2026, marking the second-best quarterly performance in the ship-owning company’s history.

Functional Brands (NASDAQ:MEHA) announced it has signed a definitive agreement to acquire the Alchemy gold-backed blockchain settlement and decentralized finance (DeFi) platform from BullionFX.

Quanta Services (NYSE:PWR) announced today that its board of directors has authorized a new $1 billion stock repurchase program and declared its latest quarterly cash distribution.

Assembly Biosciences (NASDAQ:ASMB) announced plans to expand the clinical development framework for its experimental compound ABI-6250, pushing the asset beyond its initial virology target into chronic cholestatic liver conditions.

Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.

AbbVie (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection.

Global Ship Lease (NYSE:GSL) reported elevated top-line growth and resilient cash generation for the first quarter of 2026, insulating its balance sheet from broader maritime macro-volatility through defensive multi-year charter coverage.

BioLineRx (NASDAQ:BLRX) and Hemispherian announced that two abstracts featuring their experimental oncology compound, GLIX1, will be published at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.